Skip to main content

Published locations for FDA OKs osimertinib as first adjuvant drug for NSCLC

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA OKs osimertinib as first adjuvant drug for NSCLC

User login

  • Reset your password
  • /content/fda-oks-osimertinib-first-adjuvant-drug-nsclc
  • /fedprac/article/233855/lung-cancer/fda-oks-osimertinib-first-adjuvant-drug-nsclc
  • /oncologypractice/article/233855/lung-cancer/fda-oks-osimertinib-first-adjuvant-drug-nsclc
  • /fedprac/avaho/article/233855/lung-cancer/fda-oks-osimertinib-first-adjuvant-drug-nsclc
  • /jcomjournal/article/233855/lung-cancer/fda-oks-osimertinib-first-adjuvant-drug-nsclc
  • /hematology-oncology/article/233855/lung-cancer/fda-oks-osimertinib-first-adjuvant-drug-nsclc
  • /chestphysician/article/233855/lung-cancer/fda-oks-osimertinib-first-adjuvant-drug-nsclc